The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia

被引：316

作者：

Klein, G

Vellenga, E

Fraaije, MW

Kamps, WA

de Bont, ESJM

机构：

[1] Univ Groningen Hosp, Beatrix Childrens Hosp, Div Pediat Oncol & Hematol, NL-9700 RB Groningen, Netherlands

[2] Univ Groningen Hosp, Dept Internal Med, Div Hematol, Groningen, Netherlands

[3] Univ Groningen, Biochem Lab, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2004年 / 50卷 / 02期

关键词：

matrix metalloproteinase; angiogenesis; acute myeloid leukemia; acute lymphoblastic leukemia;

D O I：

10.1016/j.critevonc.2003.09.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the past decades, a lot of effort has been put in identifying the role of matrix metalloproteinases (MMPs) in cancer. The main role of MMPs in angiogenesis, tumor growth and metastasis is degradation of extracellular matrix (ECM) and release and/or activation of growth factors through their degradative activity. The degradative activity finally results in cancer progression. NIMP-inhibitors (MMPIs) have already been designed and tested, based on the degradative role of MMPs in cancer progression. First clinical trials with MMPIs have been performed with disappointing results, showing that in order to use MNIP-inhibition the mechanisms underlying MMP-expression in cancer have to be further elucidated. This paper reviews the mechanisms of MMPs on molecular and cellular level and discusses the role for MMPs and NIMP-inhibition in cancer with special focus on acute leukemia. (C) 2003 Elsevier Ireland Ltd. All rights reserved.

引用

页码：87 / 100

页数：14

共 200 条

[1] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].

Aguayo, A ;

Kantarjian, H ;

Manshouri, T ;

Gidel, C ;

Estey, E ;

Thomas, D ;

Koller, C ;

Estrov, Z ;

O'Brien, S ;

Keating, M ;

Freireich, E ;

Albitar, M .

BLOOD, 2000, 96 (06) :2240-2245

[2] TUMOR-CELL INVASION INHIBITED BY TIMP-2 [J].

ALBINI, A ;

MELCHIORI, A ;

SANTI, L ;

LIOTTA, LA ;

BROWN, PD ;

STETLERSTEVENSON, WG .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (11) :775-779

[3] TNF-α converting enzyme (TACE) is inhibited by TIMP-3 [J].

Amour, A ;

Slocombe, PM ;

Webster, A ;

Butler, M ;

Knight, CG ;

Smith, BJ ;

Stephens, PE ;

Shelley, C ;

Hutton, M ;

Knäuper, V ;

Docherty, AJP ;

Murphy, G .

FEBS LETTERS, 1998, 435 (01) :39-44

[4]

[Anonymous], 1995, The molecular basis of cancer

[5]

Barbera-Guillem E, 2002, CANCER RES, V62, P7042

[6]

Bello L, 2001, CANCER RES, V61, P8730

[7]

BERNHARD EJ, 1990, CANCER RES, V50, P3872

[8] DIRECT EVIDENCE LINKING EXPRESSION OF MATRIX METALLOPROTEINASE-9 (92-KDA GELATINASE/COLLAGENASE) TO THE METASTATIC PHENOTYPE IN TRANSFORMED RAT EMBRYO CELLS [J].

BERNHARD, EJ ;

GRUBER, SB ;

MUSCHEL, RJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (10) :4293-4297

[9] Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter [J].

Bian, JH ;

Sun, Y .

MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (11) :6330-6338

[10] Inhibition of articular cartilage degradation in culture by a novel nonpeptidic matrix metalloproteinase inhibitor [J].

Billinghurst, RC ;

O'Brien, K ;

Poole, AR ;

McIlwraith, CW .

INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 :594-597

← 1 2 3 4 5 6 7 8 9 10 →